I wrote that it will be one of the most expensive approved products to produced (not the most expensive) that Car-T is much more complex, can be more expensive is not an argument against what I writes ..
Kymriah and Yescarta (Car-T Lymphoma Treatments) both cost about $700,000 for 85% of patients, and the other 15% paid over $1 million for treatment. Both drugs were approved and 2017 and 2018, respectively by the FDA. DCVax will most likely cost $175-225k so you point about DC Vax being one of the most expensive cancer treatments isn't correct. If in fact these DC Vax estimates hold up, it will be one of the cheapest cancer treatments with pretty much zero complications and a very favorable life expectancy increase. As might know, even the SOC for most cancers, chemo, has a higher cost than the actual cost of chemotherapy because of the all complications..ie more drugs and treatment to offset the side effects of chemo. Also,one would have to imagine Flaskworks will bring the cost down even more, once approved.
My mother took Humira for Crohns....cost in 2008 was over $10k for 30 day supply or $120k a year. Perspective.
While I 100% agree there are uncertainties surrounding NWBO, cost isn't one of them.
Market Data 
Markets 
AI
